Clinical Experience of Chinese Herbal Medicine Ameliorates Dermatologic Events from Epidermal Growth Factor Receptor Inhibitors for Lung Cancer: A Case Series

In recent years, new biologically targeted therapies that interfere with specific molecular pathways to affect the progression of cancer have been developed as indispensable options for patients who are intolerant of or fail to respond to chemotherapy.1 A number of agents are already approved by the Food and Drug Administration.2 Among them, epidermal growth factor receptor (EGFR) inhibitors are used to treat advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR mutation who have never smoked, and such inhibitors have shown significant therapeutic benefits.
Source: Explore - Category: Nursing Authors: Source Type: research